Terrence Delikat, DO
Family Medicine · Bartow, FLNPI 1154326775
Payments from drug & device makers
Across 285 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$775
- AstraZeneca$686
- Pfizer$570
- GSK$448
- Lilly USA, LLC$362
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,20019%
- Speaking & faculty fees$1202%
- Travel & lodging$851%
- Food & beverage$5,02778%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 5 | $1,332 |
| AbbVie(2 entities) | 49 | $775 |
| AstraZeneca | 44 | $686 |
| Pfizer | 26 | $570 |
| GSK | 20 | $448 |
| Lilly USA, LLC | 19 | $362 |
| Amgen(2 entities) | 11 | $294 |
| Novo Nordisk | 14 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $201 |
| Merck | 10 | $182 |
| Johnson & Johnson | 8 | $129 |
| Sanofi-aventis U.S. LLC | 3 | $120 |
| Boehringer Ingelheim | 7 | $108 |
| Novartis | 6 | $106 |
| Idorsia Pharmaceuticals US Inc | 5 | $88 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Abbott | 6 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| Exact Sciences | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $66 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| Boston Scientific | 1 | $45 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $31 |
| Almatica Pharma LLC | 2 | $30 |
| Evoke Pharma, Inc. | 2 | $28 |
| Shield Therapeutics Inc | 2 | $27 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Bayer | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Kvk-tech, Inc. | 3 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- Repatha$125
How this compares
$6,458 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $83,087 |
| TrulicityDulaglutide | 46 | $54,207 |
| FarxigaDapagliflozin Propanediol | 59 | $39,773 |
| LinzessLinaclotide | 57 | $35,280 |
| XifaxanRifaximin | 11 | $33,852 |
| JardianceEmpagliflozin | 33 | $33,459 |
| XareltoRivaroxaban | 43 | $33,199 |
| OzempicSemaglutide | 26 | $30,273 |
| MounjaroTirzepatide | 26 | $27,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $25,025 |
| EntrestoSacubitril/Valsartan | 22 | $21,250 |
| VraylarCariprazine Hcl | 14 | $20,269 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $20,137 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $19,939 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $19,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humulin N | $362 | $84,43385 claims |
| PfizerEliquis | $570 | $83,087107 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $686 | $82,627146 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $108 | $73,41396 claims |
| AbbVieLinzess, Vraylar | $775 | $55,54971 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $201 | $33,85211 claims |
| Johnson & JohnsonXarelto | $129 | $33,19943 claims |
| Novo NordiskOzempic | $245 | $30,27326 claims |
| GSKTrelegy Ellipta | $448 | $25,02528 claims |
| NovartisEntresto | $106 | $21,25022 claims |
| MerckJanuvia | $182 | $16,30224 claims |
| BayerKerendia | $25 | $7,13111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Bartow
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.